SEARCH

SEARCH BY CITATION

References

  • 1
    Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002; 2: 19.
  • 2
    Lerut JP. Avoiding steroids in solid organ transplantation. Transpl Int 2003; 16: 213.
  • 3
    Matas AJ. What's new and what's hot in transplantation: clinical science ATC 2003. Am J Transplant 2003; 3: 1465.
  • 4
    Marsh C. Calcineurin-sparing or steroid-sparing immunosuppression in renal transplantation. Currt Opin Organ Transplant 2002; 7: 145.
  • 5
    Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853.
  • 6
    Krämer BK, Zülke C, Kammerl MC, et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982.
  • 7
    Kirk AD, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. Transplant International 2005; 18: 2.
  • 8
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J, for the Rapamune Study Group. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68: 1526.
  • 9
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, for the Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant recipients after early cyclosporine elimination. Transplantation 2002; 74: 1560.
  • 10
    Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study. Transplantation 2003; 76: 364.
  • 11
    Alexander JW, McIntosh MJ, Goodman HR, et al. The influence of immunomodulatory diets on transplant success and complications. Transplantation 2005; 79: 460.
  • 12
    Gibson SW, Valente JF, Alexander JW, et al. Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. Transplantation 2000; 69: 2034.
  • 13
    Gibson SW, Valente JF, Alexander JW, Custer DA, Babcock GF, Ogle CK. The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenolate mofetil, cyclsoporine A, and donor-specific transfusion. J Heart Lung Transplant 1999; 18: 185.
  • 14
    Levy AE, Alexander JW. Nutritional immunomodulation enhances cardiac allograft survival in rats treated with donor specific transfusion and CsA. Transplantation 1995; 60: 812.
  • 15
    Alexander JW, Valente JF, Greenberg NA, et al. Dietary amino acids as new and novel agents to enhance allograft survival. Nutrition 1999; 15: 130.
  • 16
    Davidson J, Wilkinson A. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: SSI.
  • 17
    Birkeland SA. Steroid-free immunosuppression in renal transplantation. A long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089.
  • 18
    Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immuosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13.
  • 19
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra Jr O. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331.
  • 20
    Cantarovich D, Giral-Classe M, Hourmant M, et al. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation. Nephrol Dial Transplant 2000; 15: 1673.
  • 21
    Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845.
  • 22
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss Ge JR. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396.
  • 23
    Pirenne J, Aerts R, Koshiba T, et al. Steroid-free immunosuppression during and after liver transplantation – a 3-year follow-up report. Clin Transplant 2003; 17: 177.
  • 24
    Reding R, Gras J, Sokal E, Otte J-B, Davies HFS. Steroid-free liver transplantation in children. Lancet 2003; 362: 2068.
  • 25
    Kaufman DB, Baker MS, Chen X, Leventhal JR, Stuart FP. Sequential kidney/islet transplantation using prednisone-free immunosuppression. Am J Transplant 2002; 2: 674.
  • 26
    Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
  • 27
    Cantarovich D, Giral-Classe M, Hourmant M, et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000; 69: 1505.
  • 28
    Bodziak KA, Hricik DE. Minimizing the side effects of immunosuppression in kidney transplant patients. Curr Opin Organ Transplant 2003; 8: 160.
  • 29
    Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
  • 30
    Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
  • 31
    Grinyó JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transplant Int 2003; 16: 820.
  • 32
    Jolicoeur EM, Qi S, Xu D, Dumont L, Daloze P, Chen H. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 2003; 75: 54.
  • 33
    Klupp J, Dambrin C, Hibi K, et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Am J Transplant 2003; 3: 817.
  • 34
    Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(Suppl. 3A): 7S.
  • 35
    Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002; 106: 1610.
  • 36
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
  • 37
    Bostom AD, Brown RS Jr, Chavers BM, et al. Prevention of post-transplant cardiovascular disease – report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491.
  • 38
    Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease. A new paradigm. Am J Kidney Dis 2000; 35: S117.
  • 39
    Evoy D, Lieberman MD, Fahey III TJ, Daly JM. Immunonutrition: the role of arginine. Nutrition 1998; 14: 611.
  • 40
    Alexander JW. Immunonutrition – the role of ω-3 fatty acids. Nutrition 1998; 14: 627.
  • 41
    Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773.